Noel et al. (2023) investigated the roles of the novel immune checkpoint molecule T cell immunoreceptor with Ig and immunoreceptor tyrosine-based inhibitory motif domains (TIGIT) in kidney T cells and AKI outcomes. TIGIT expression increased in mouse and kidney T cells, which would lead to worse AKI outcomes. Thus, it might be a potential therapeutic target for AKI. A experimental study (Packialakshmi et al., 2020) have demonstrated innate immune system is a leading cause to AKI (Uchida et al., 2023). Here, TIGIT is linked to acute kidney injury.